Clinical trialPhase 1 / Phase 2Completed
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours
- Outcome
- Results posted; no analysis attached
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 3 December 2018
- Ended
- 31 October 2023
- Enrollment
- 216 participants
- Sites
- 11
- Primary outcomes
- Dose Limiting Toxicities (DLT) in the Trial Subjects.; Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability); The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.; The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
- Sponsor type
- Industry
- Results posted
- 2 April 2025
- Last update
- 2 April 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 2 April 2025
- DLT/MTD
- Dose Limiting Toxicities (DLT) in the Trial Subjects.FP-1305 (Bexmarilimab) 0.3 mg/kg: 0, n = 13FP-1305 (Bexmarilimab) 1 mg/kg: 0, n = 130FP-1305 (Bexmarilimab) 3 mg/kg: 0, n = 41FP-1305 (Bexmarilimab) 10 mg/kg: 0, n = 18FP-1305 (Bexmarilimab) 0.1 mg/kg: 0, n = 5FP-1305 (Bexmarilimab) 30 mg/kg: 0, n = 9Values: DLTTime frame: Up to one yearNo analysis posted for this outcome (outcome 1)
- Primary outcome
- Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)FP-1305 (Bexmarilimab) 0.3 mg/kg: 13 of 13FP-1305 (Bexmarilimab) 1 mg/kg: 122 of 130FP-1305 (Bexmarilimab) 3 mg/kg: 38 of 41FP-1305 (Bexmarilimab) 10 mg/kg: 17 of 18FP-1305 (Bexmarilimab) 0.1 mg/kg: 5 of 5FP-1305 (Bexmarilimab) 30 mg/kg: 9 of 9Values: ParticipantsTime frame: approximately 4 years and 9 monthsNo analysis posted for this outcome (outcome 2)
- ORR
- The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.FP-1305 (Bexmarilimab) 0.3 mg/kg: 1 of 13FP-1305 (Bexmarilimab) 1 mg/kg: 0 of 130FP-1305 (Bexmarilimab) 3 mg/kg: 0 of 41FP-1305 (Bexmarilimab) 10 mg/kg: 0 of 18FP-1305 (Bexmarilimab) 0.1 mg/kg: 0 of 5FP-1305 (Bexmarilimab) 30 mg/kg: 0 of 9Values: ParticipantsTime frame: approximately 4 years and 9 monthsNo analysis posted for this outcome (outcome 3)
- DCR
- The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.FP-1305 (Bexmarilimab) 0.3 mg/kg: 1 of 13FP-1305 (Bexmarilimab) 1 mg/kg: 20 of 130FP-1305 (Bexmarilimab) 3 mg/kg: 4 of 41FP-1305 (Bexmarilimab) 10 mg/kg: 2 of 18FP-1305 (Bexmarilimab) 0.1 mg/kg: 0 of 5FP-1305 (Bexmarilimab) 30 mg/kg: 1 of 9Values: ParticipantsTime frame: approximately 4 years and 9 monthsNo analysis posted for this outcome (outcome 4)
- Participants
- FP-1305 (Bexmarilimab) 0.3 mg/kg: 13 started, 13 completedFP-1305 (Bexmarilimab) 1 mg/kg: 130 started, 130 completedFP-1305 (Bexmarilimab) 3 mg/kg: 41 started, 41 completedFP-1305 (Bexmarilimab) 10 mg/kg: 18 started, 18 completedFP-1305 (Bexmarilimab) 0.1 mg/kg: 5 started, 5 completedFP-1305 (Bexmarilimab) 30 mg/kg: 9 started, 9 completed
- Serious adverse events
- FP-1305 (Bexmarilimab) 0.3 mg/kg: 1 of 13FP-1305 (Bexmarilimab) 1 mg/kg: 57 of 130FP-1305 (Bexmarilimab) 3 mg/kg: 13 of 41FP-1305 (Bexmarilimab) 10 mg/kg: 10 of 18FP-1305 (Bexmarilimab) 0.1 mg/kg: 3 of 5FP-1305 (Bexmarilimab) 30 mg/kg: 4 of 9Participants with at least one serious adverse event, of those at risk, as posted
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Dose Limiting Toxicities (DLT) in the Trial Subjects. [Up to one year]. Number, DLT. FP-1305 (Bexmarilimab) 0.3 mg/kg (n=13): 0; FP-1305 (Bexmarilimab) 1 mg/kg (n=130): 0; FP-1305 (Bexmarilimab) 3 mg/kg (n=41): 0; FP-1305 (Bexmarilimab) 10 mg/kg (n=18): 0; FP-1305 (Bexmarilimab) 0.1 mg/kg (n=5): 0; FP-1305 (Bexmarilimab) 30 mg/kg (n=9): 0.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) [approximately 4 years and 9 months]. Count Of Participants, Participants. FP-1305 (Bexmarilimab) 0.3 mg/kg (n=13): 13; FP-1305 (Bexmarilimab) 1 mg/kg (n=130): 122; FP-1305 (Bexmarilimab) 3 mg/kg (n=41): 38; FP-1305 (Bexmarilimab) 10 mg/kg (n=18): 17; FP-1305 (Bexmarilimab) 0.1 mg/kg (n=5): 5; FP-1305 (Bexmarilimab) 30 mg/kg (n=9): 9.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1. [approximately 4 years and 9 months]. Count Of Participants, Participants. FP-1305 (Bexmarilimab) 0.3 mg/kg (n=13): 1; FP-1305 (Bexmarilimab) 1 mg/kg (n=130): 0; FP-1305 (Bexmarilimab) 3 mg/kg (n=41): 0; FP-1305 (Bexmarilimab) 10 mg/kg (n=18): 0; FP-1305 (Bexmarilimab) 0.1 mg/kg (n=5): 0; FP-1305 (Bexmarilimab) 30 mg/kg (n=9): 0.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1. [approximately 4 years and 9 months]. Count Of Participants, Participants. FP-1305 (Bexmarilimab) 0.3 mg/kg (n=13): 1; FP-1305 (Bexmarilimab) 1 mg/kg (n=130): 20; FP-1305 (Bexmarilimab) 3 mg/kg (n=41): 4; FP-1305 (Bexmarilimab) 10 mg/kg (n=18): 2; FP-1305 (Bexmarilimab) 0.1 mg/kg (n=5): 0; FP-1305 (Bexmarilimab) 30 mg/kg (n=9): 1.
Papers 3
- Builds on itBexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MA… DOI 10.1016/j.xcrm.2023.101307↗
- Builds on itNonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cance… DOI 10.1158/1535-7163.mct-21-0840↗
- Builds on itSystemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients wi… DOI 10.1158/1078-0432.ccr-20-4862↗